恶性肿瘤患者的免疫功能状态及免疫治疗研究进展

王俞; 崔书中

doi:10.3969/j.issn.1000-8179.20131206

恶性肿瘤患者的免疫功能状态及免疫治疗研究进展

doi: 10.3969/j.issn.1000-8179.20131206

王俞,
崔书中^,

广州医科大学附属肿瘤医院腹外二科（广州市 510095）

基金项目:

广州医学院博士、留学回国人员科研项目 2012c66

详细信息

作者简介:
王俞硕士研究生。研究方向为腹部肿瘤的临床和基础研究。E-mail：wangyu2011125@126.com

通讯作者:
崔书中 cuishuzhong@126.com

计量
- 文章访问数: 75
- HTML全文浏览量: 3
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2013-07-29
- 修回日期: 2014-03-02
- 刊出日期: 2014-07-15

Research progress in immune function of patients with malignant tumors and immunotherapy for cancers

WANG Yu,
CUI Shuzhong^,

No.2 Department of Abdominal Surgery, The Affiliated Oncologic Hospital of Guangzhou Medical University, Guangzhou 510095, China

Funds:

the scientific research project of doctor and returned overseas students form Guangzhou Medical University 2012c66

More Information

Corresponding author: Shuzhong CUI; E-mail: cuishuzhong@126.com

摘要

摘要: 观察恶性肿瘤患者的免疫状态，分析恶性肿瘤的发生、发展，在判断患者预后和抗肿瘤治疗疗效上有一定的意义。荷瘤宿主多存在细胞免疫功能紊乱，临床上采用检测外周血淋巴细胞亚群和其他免疫细胞来评估患者的免疫状态。此外，随着肿瘤学、免疫学以及分子生物学等相关学科的迅速发展和交叉渗透，肿瘤免疫治疗的研究突飞猛进，已成为继手术、放射治疗和化学治疗之后又一种重要的抗肿瘤治疗手段，为恶性肿瘤患者的治疗带来新的希望。本文就恶性肿瘤患者的免疫功能状态及免疫治疗研究进展进行综述。
- 恶性肿瘤 /
- 淋巴细胞亚群 /
- 树突状细胞 /
- 髓源抑制性细胞 /
- 免疫治疗
Abstract: Observing the immune function of patients with malignant tumor has a specific significance in the evaluation of the occurrence and development of cancer and in judging patient prognosis and efficacy of anti-cancer therapy. Tumor-bearing hosts often show dysfunction in cellular immunity. In clinics, we often detect lymphocyte subsets and other immunocytes to evaluate the condition of the patient's immunity. Given the rapid development and cross-penetration of oncology, immunology, molecular biology, and other related disciplines, tumor immunotherapy has now become another important anti-tumor treatment following surgery, radiation therapy, and chemotherapy, and it is also now a new approach in treating cancer. This review focuses on the progress of the immune function of patients with malignant tumors and on the immunotherapy for cancers.
- malignant tumor /
- lymphocyte subsets /
- dendritic cells /
- myeloid-derived suppressor cells /
- immunotherapy

HTML全文

参考文献(28)

[1]	Das S, Karim S, Datta Ray C, et al. Peripheral blood lymphocyte subpopulations in patients with cervical cancer[J]. Int J Gynaecol Obstet, 2007, 98(2):143-146. doi: 10.1016/j.ijgo.2007.04.011
[2]	Liu G, Ren H, Sun XJ, et al. Distribution of natural killer cells and T-lymphocyte subsets in peripheral blood, gallbladder cancer and surrounding tissue[J]. Hepatobiliary Pancreat Dis Int, 2007, 6(1):81-86. http://cn.bing.com/academic/profile?id=6626b62e8ffd4398e69b7d0ab598da1a&encoded=0&v=paper_preview&mkt=zh-cn
[3]	Wang L, Shen Y. Imbalance of circulating T-lymphocyte subpopulation in gastric cancer patiens correlated with performance status [J]. Clin Lab, 2013, 59(3-4):429-433. https://pubmed.ncbi.nlm.nih.gov/23724636/
[4]	Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone I. definition according to profiles of lymphokine activities and secreted proteins. 1986[J]. J Immunol, 2005, 175 (1):5-14. http://cn.bing.com/academic/profile?id=bb42a741b77967fed144da4b0230db52&encoded=0&v=paper_preview&mkt=zh-cn
[5]	Ehi K, Ishigami S, Masamoto I, et al. Analysis of T-helper type 1 and 2 cells and T-cytotoxic type 1 and 2 cells of sentinel lymph nodes in breast cancer[J]. Oncol Rep, 2008, 19(3):601-607. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=500186cf4527d8fa33d7739eb5a00eac
[6]	Lang F, Linlin M, Ye T, et al. Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder[J]. J Clin Lab Anal, 2012, 26(5): 365-371. doi: 10.1002/jcla.21532
[7]	Podhorecka M, Dmoszynska A, Rolinski J, et al. T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia-the three-color flow cytometry analysis[J]. Leuk Res, 2002, 26(7): 657-660. doi: 10.1016/S0145-2126(01)00194-1
[8]	王长印, 邹雄, 车至香, 等.消化道肿瘤患者Th1/Th2细胞的监测和分析[J].现代免疫学, 2004, 24(1): 72-76. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=shmyxzz200401020 Wang CY, Zou X, Che ZX, et al. The monitoring and analysis of Th1/Th2 cells in patients with gastrointestinal cancer[J]. Current Immunology, 2004, 24(1):72-76. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=shmyxzz200401020
[9]	卢晓婷, 刘俊田.CD4⁺CD25⁺调节性T细胞在肿瘤免疫及化疗方面的研究进展[J].中国肿瘤临床, 2008, 35(11):656-658. http://journal11.magtechjournal.com/Jwk_zgzllc/CN/abstract/abstract11089.shtml Lu XT, Liu JT. Advancements in the research on CD4⁺CD25⁺regulatory T cells in tumor immunity and chemotherapy[J]. Chin J Clin Oncol, 2008, 35(11):656-658. http://journal11.magtechjournal.com/Jwk_zgzllc/CN/abstract/abstract11089.shtml
[10]	Sasada T, Kimura M, Yoshida Y, et al. CD4⁺CD25⁺ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression[J]. Cancer, 2003, 98(5):1089-1099. doi: 10.1002/cncr.11618
[11]	Lee WC, Wu TJ, Chou HS, et al. The impact of CD4⁺CD25⁺T cells in the tumor microenvironment of hepatocellular carcinoma[J]. Surgery, 2012, 151(2):213-222. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=6d979825937768f51ad525208142b3c8
[12]	Jadidi-Niaragh F, Yousefi M, Memarian A, et al. Increased frequency of CD8⁺ and CD4⁺ regulatory T cells in chronic lymphocytic leukemia: association with disease progression[J]. Cancer Invest, 2013, 31(2):121-131. doi: 10.3109/07357907.2012.756110
[13]	Bacic D, Uravic M, Bacic R, et al. Augmentation of regulatory T cells (CD4⁺CD25⁺Foxp3⁺) correlates with tumor stage in patients with colorectal cancer[J]. Coll Antropol, 2011, 35(Suppl 2):65-68. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Open J-Gate000003891111
[14]	Steinman RM. Decisions about dendritic cells: past, present, and future[J]. Annu Rev Immunol, 2012, 30:1-22. doi: 10.1146/annurev-immunol-100311-102839
[15]	Nefedova Y, Cheng P, Gilkes D, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling[J]. J Immunol, 2005, 175(7): 4338-4346. doi: 10.4049/jimmunol.175.7.4338
[16]	周卸来, 黄茵, 王芳, 等.肿瘤细胞表达Sema3A对树突状细胞功能的影响[J].浙江大学学报(医学版), 2010, 39(4):364-369. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zjdxxb-yxb201004005 Zhou XL, Huang Y, Wang F, et al. Effects of Sema3A derived from tumor cells on functions of dendritic cells[J]. J Zhejiang Univ(Medical Sci), 2010, 39(4):364-369. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zjdxxb-yxb201004005
[17]	Duffy A, Zhao F, Haile L, et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies[J]. Cancer Immunol Immunother, 2013, 62(2):299-307. doi: 10.1007/s00262-012-1332-3
[18]	Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells[J]. Cancer Res, 2008, 68(8): 2561-2563. doi: 10.1158/0008-5472.CAN-07-6229
[19]	杜伟娇, 于津浦, 李慧, 等.肿瘤诱导的髓系来源抑制细胞中IDO表达相关机制研究[J].中国肿瘤临床, 2011, 38(7):372-376. http://journal11.magtechjournal.com/Jwk_zgzllc/CN/abstract/abstract8578.shtml Du WJ, Yu JP, Li H, et al. Expression of IDO in tumor induced myeloid-derived suppressor cells and its mechanism[J]. Chin J Clin Oncol, 2011, 38(7): 372-376. http://journal11.magtechjournal.com/Jwk_zgzllc/CN/abstract/abstract8578.shtml
[20]	Martin F, Apetoh L, Ghiringhelli F. Role of myeloid-derived suppressor cells in tumor immunotherapy[J]. Immunotherapy, 2012, 4(1): 43-57. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=d788f990f72ca54aa84f033ac06e67a1
[21]	Yoshikawa T, Tsuburaya A, Kobayashi O, et al. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma[J]. Hepatogastroenterology, 2003, 50(54):2259-2263. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b0db71903eb61dec90862cbee4ab61bb
[22]	Tanaka H, Muguruma K, Ohira M, et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer[J]. Anticancer Res, 2012, 32(8):3427-3433. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=317152d294dc8b04dc3a6e758082e7e0
[23]	Hamuro J. Anticancer immunotherapy with perorally effective lentinan[J]. Gan To Kagaku Ryoho, 2005, 32(8):1209-1215. http://cn.bing.com/academic/profile?id=9a215db351f6a21b916fd46daf5e550d&encoded=0&v=paper_preview&mkt=zh-cn
[24]	Hernandez-Alcoceba R, Sangro B, Berraondo P, et al. Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives[J]. Expert Opin Investig Drugs, 2013, 22(7):827-841. doi: 10.1517/13543784.2013.793307
[25]	Vacchelli E, Eggermont A, Fridman WH, et al. Trial watch: adoptive cell transfer for anticancer immunotherapy[J]. Oncoimmunology, 2013, 2(5):e24238. doi: 10.4161/onci.24238
[26]	Bighin C, Pronzato P, Del Mastro L. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients[J]. Future Oncol, 2013, 9(7):955-957. doi: 10.2217/fon.13.74
[27]	Stephens DM, Byrd JC. Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy [J]. Hematol Oncol Clin North Am, 2013, 27(2):303-327. doi: 10.1016/j.hoc.2012.12.003
[28]	Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science[J]. Immunity, 2008, 29(3):319-324. doi: 10.1016/j.immuni.2008.08.001